SourceBio International's () Jay LeCoque talks to Proactive London's Katie Pilbeam ahead of their IPO on AIM.
He explains that Covid-19 is now their main focus, to support the government effort to get the pandemic testing campaign under control.
The IPO, values the company at £120m, which Jay LeCoque says is the 'right time to do it and the support from the city underscores it's the right decision to do it now.'
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of SourceBio International PLC named herein, including the promotion by the Company of SourceBio International PLC in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE